GILEAD SCIENCES, INC. GILD
Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as "Gilead," the "company," "we," "our" or "us") is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California.
We have transformed care for people around the world by discovering, developing and delivering innovative medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Our innovative medicines represent advancements by offering first-in-class therapies, greater efficacy, enhanced modes of delivery, more convenient treatment and prevention regimens, improved resistance profiles and reduced side effects.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.44B | $28.75B | $27.12B | $27.28B | $27.30B | $24.69B | $22.45B | $22.13B | $26.11B | $30.39B |
| Cost of revenue | $6.23B | $6.25B | $6.50B | $5.66B | $6.60B | $4.57B | $4.67B | $4.85B | $4.37B | $4.26B |
| Gross profit | $23.21B | $22.50B | $20.62B | $21.62B | $20.70B | $20.12B | $17.77B | $17.27B | $21.74B | $26.13B |
| R&D | — | — | — | — | — | — | $9.11B | $5.02B | $3.73B | $5.10B |
| SG&A | $5.77B | $6.09B | $6.09B | $5.67B | $5.25B | $5.15B | $4.38B | $4.06B | $3.88B | $3.40B |
| Total operating expenses | $19.42B | $27.09B | $19.51B | $19.95B | $17.39B | $20.62B | $18.16B | $13.93B | $11.98B | $12.76B |
| Operating income | $10.02B | $1.66B | $7.61B | $7.33B | $9.92B | $4.07B | $4.29B | $8.20B | $14.12B | $17.63B |
| Interest expense | $1.02B | $977.0M | $944.0M | $935.0M | $1.00B | $984.0M | $995.0M | $1.08B | $1.12B | $964.0M |
| Pre-tax income | $9.80B | $690.0M | $6.86B | $5.81B | $8.28B | $1.67B | $5.16B | $7.80B | $13.53B | $17.10B |
| Income tax | $1.29B | $211.0M | $1.25B | $1.25B | $2.08B | $1.58B | $204.0M | $2.34B | $8.88B | $3.61B |
| Net income | $8.51B | $480.0M | $5.67B | $4.59B | $6.22B | $123.0M | $5.39B | $5.46B | $4.63B | $13.50B |
| EPS, basic | 6.84 | 0.38 | 4.54 | 3.66 | 4.96 | 0.10 | 4.24 | 4.20 | 3.54 | 10.08 |
| EPS, diluted | 6.78 | 0.38 | 4.50 | 3.64 | 4.93 | 0.10 | 4.22 | 4.17 | 3.51 | 9.94 |
| Shares, diluted (wtd. avg.) | $1.25B | $1.25B | $1.26B | $1.26B | $1.26B | $1.26B | $1.28B | $1.31B | $1.32B | $1.36B |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.56B | $9.99B | $6.08B | $5.41B | $5.34B | $6.00B | $11.63B | $17.94B | $7.59B | $8.23B |
| Short-term investments | $68.0M | $0 | $1.18B | $973.0M | $1.18B | $1.41B | $12.72B | $12.15B | $17.92B | $3.67B |
| Receivables | $4.91B | $4.42B | $4.66B | $4.78B | $4.49B | $4.89B | $3.58B | $3.33B | $3.85B | $4.51B |
| Inventory | $1.77B | $1.71B | $1.79B | $1.51B | $1.62B | $1.68B | $922.0M | $814.0M | $801.0M | $1.59B |
| Total current assets | $18.34B | $19.17B | $16.09B | $14.44B | $14.77B | $16.00B | $30.30B | $35.84B | $31.82B | $19.59B |
| Property, plant and equipment | $5.61B | $5.41B | $5.32B | $5.47B | $5.12B | $4.97B | $4.50B | $4.01B | $3.29B | $2.87B |
| Goodwill | $8.31B | $8.31B | $8.31B | $8.31B | $8.33B | $8.11B | $4.12B | $4.12B | $4.16B | $1.17B |
| Other intangibles | $16.98B | $19.95B | $26.45B | $28.89B | $33.45B | $33.13B | $13.79B | $15.74B | $17.10B | $8.97B |
| Total assets | $59.02B | $58.99B | $62.12B | $63.17B | $67.95B | $68.41B | $61.63B | $63.67B | $70.28B | $56.98B |
| Accounts payable | $715.0M | $833.0M | $550.0M | $905.0M | $705.0M | $844.0M | $713.0M | $790.0M | $814.0M | $1.21B |
| Short-term debt | $2.81B | $1.81B | $1.80B | $2.27B | $1.52B | $2.76B | $2.50B | $2.75B | $2.75B | $0 |
| Total current liabilities | $11.81B | $12.00B | $11.28B | $11.24B | $11.61B | $11.40B | $9.76B | $10.61B | $11.63B | $9.22B |
| Long-term debt | $22.13B | $24.90B | $23.19B | $22.96B | $25.18B | $28.64B | $22.09B | $24.57B | $30.80B | $26.35B |
| Retained earnings | $13.73B | $11.50B | $16.30B | $15.69B | $16.32B | $14.38B | $19.39B | $19.02B | $19.01B | $18.15B |
| Total equity | $22.70B | $19.33B | $22.75B | $21.21B | $21.06B | $18.22B | $22.65B | $21.53B | $20.50B | $19.36B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $10.02B | $10.83B | $8.01B | $9.07B | $11.38B | $8.17B | $9.14B | $8.40B | $11.90B | $17.05B |
| Depreciation and amortisation | $370.0M | $381.0M | $354.0M | $323.0M | $329.0M | $288.0M | $255.0M | $226.0M | $233.0M | $177.0M |
| Stock-based compensation | $894.0M | $835.0M | $766.0M | $637.0M | $635.0M | $643.0M | $636.0M | $845.0M | $638.0M | $380.0M |
| Capital expenditure | $563.0M | $523.0M | $585.0M | $728.0M | $579.0M | $650.0M | $825.0M | $924.0M | $590.0M | $748.0M |
| Investing cash flow | -$4.79B | -$3.45B | -$2.27B | -$2.47B | -$3.13B | -$14.62B | -$7.82B | $14.36B | -$16.07B | -$11.98B |
| Financing cash flow | -$7.75B | -$3.43B | -$5.12B | -$6.47B | -$8.88B | $770.0M | -$7.63B | -$12.32B | $3.39B | -$9.72B |
| Dividends paid | $4.00B | $3.92B | $3.81B | $3.71B | $3.60B | $3.45B | $3.22B | $2.97B | $2.73B | $2.46B |
| Buybacks | $1.92B | $1.15B | $1.00B | $1.40B | $546.0M | $1.58B | $1.75B | $2.90B | $954.0M | $11.00B |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000882095-26-000006.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |
| HALO | HALOZYME THERAPEUTICS, INC. | $12.51B | 43.0x | 37.6% |